Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4862MR)

This product GTTS-WQ4862MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4862MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1850MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ11317MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ4095MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ432MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ6538MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ10158MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ7040MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ14728MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW